bioAffinity Partners with AvMEDICAL to Expand Veteran Access to Lung Cancer Test
Event summary
- bioAffinity Technologies and AvMEDICAL debuted their distribution agreement at the NAVREF 2026 Annual Conference, targeting veteran access to CyPath Lung.
- The partnership aims to expand government and agency access to CyPath Lung via AvMEDICAL’s federal healthcare distribution channels.
- CyPath Lung demonstrated 92% sensitivity, 87% specificity, and 99% negative predictive value in detecting lung cancer in high-risk patients.
- bioAffinity also presented CyPath Lung at the GO2 for Lung Cancer Screening and Care Conference to extend outreach to the lung cancer screening community.
The big picture
The partnership between bioAffinity and AvMEDICAL addresses a critical health burden among veterans, with approximately 7,700 veterans diagnosed with lung cancer annually. This strategic collaboration leverages AvMEDICAL’s federal healthcare distribution capabilities to improve access to early detection tools, aligning with broader industry trends toward noninvasive diagnostic solutions and targeted healthcare outreach for high-risk populations.
What we're watching
- Government Adoption
- How quickly bioAffinity and AvMEDICAL can secure government contracts and procurement approvals for CyPath Lung.
- Market Expansion
- Whether the partnership can sustain growth in demand for CyPath Lung following key conferences.
- Regulatory Compliance
- The pace at which bioAffinity can maintain and expand adoption of CyPath Lung as a Laboratory Developed Test under evolving CLIA regulations.
Related topics